NCT01176747已完成1 期
In-vivo Deposition Measurement of Beclometasone and Formoterol After Inhalation of a Single Dose of the Combination BDP Plus Formoterol NEXT DPI in Healthy Volunteers, Asthmatic and COPD Patients.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Lung deposition of BDP and Formoterol (expressed as % of emitted dose) when inhaled using the NEXT dry powder inhaler
研究概览
简要总结
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone and Formoterol using a gamma-scintigraphic technique after inhalation of a single dose of 99mTc-radiolabelled BDP/formoterol fixed combination administered Via the NEXT DPI in healthy volunteers, asthmatic and COPD patients. Additionally, the systemic exposures to formoterol, BDP and its monopropionate metabolite (B17MP) will be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers:
- •Males and females aged 18-65 years;
- •Body Mass Index (BMI) between 18.0 and 28.0 kg/m2;
- •Non- or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year;
- •Normal blood pressure and heart rate;
- •Normal electrocardiogram (ECG,12 lead);
- •Normal laboratory tests;
- •Patients with Asthma:
- •Males and females aged 21-65 years;
- •BMI between 18.0 and 28.0 kg/m2;
- •Non- or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year;
- •Normal blood pressure and heart rate;
- •Normal ECG (12 lead);
- •FEV1 ≥ 30% and < 80% of predicted according to European Coal and Steel Community values (ECSC)
- •Reversibility of FEV1 ≥ 12% and at least 200 ml of the initial value 15 minutes after inhalation of 200 µg Salbutamol;
- •Patients with COPD:
- •Males and females aged 40 - 70 years
- •BMI between 18.0 and 30.0 kg/m2;
- •Normal blood pressure and heart rate;
- •Normal ECG (12 lead);
- •Stable COPD within the past 4 weeks;
- •Post bronchodilator FEV1 between 30% and 50% predicted values (ECSC);
- •Post bronchodilator FEV1/FVC < 0.70 (absolute value);
- •Minimum smoking history of 10 pack-years;
排除标准
- •All subjects:
- •Blood donation or blood loss in the previous 8 weeks;
- •Positive HIV1 or HIV2 serology;
- •Positive acute or chronic Hepatitis B or Hepatitis C;
- •Unsuitable veins for repeated venipuncture;
- •Female patients: pregnant, positive pregnancy test, lactating mother or lack of efficient contraception.
- •History of substance abuse or positive urine drug screen;
- •Abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation;
- •Uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric clinically significant disorder;
- •Participation in another clinical trial in the previous 8 weeks; participation in study using radioactive material within 1 calendar year;
- •Known sensitivity to Formoterol or Beclometasone or any of the excipients;
- •Concomitant severe diseases or diseases which are contra indications for the use of inhaled Beta-2-agonist or steroids;
- •Use of any prescription drug for which concomitant beta-agonist or steroid administration are contraindicated;
- •Recent relevant infectious disease (less than two months);
- •Flu vaccination or other vaccination within 4 weeks prior to the screening visit;
- •Additional exclusion criteria for healthy volunteers:
- •Lung function measurements outside normal limits (normal values: FEV1/FVC > 0.70 and FEV1 and FVC > 80% for the ECSC predicted values);
- •Additional exclusion criteria for patients with Asthma:
- •Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months;
- •Life-threatening/unstable respiratory status within the previous 30 days;
- •Requirement of supplemental oxygen therapy;
- •Change in dose or type of any medications for asthma within 4 weeks prior to the screening visit;
- •Asthma exacerbation within the 4 weeks prior to inclusion.
- •Additional exclusion criteria for patients with COPD:
- •Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months;
- •Life-threatening/unstable respiratory status within the previous 30 days;
- •Requirement of supplemental oxygen therapy;
- •Change in dose or type of any medications for COPD within 4 weeks prior to the screening visit;
- •COPD exacerbation within the 4 weeks prior to inclusion;
- •History of asthma or any chronic respiratory diseases other than COPD.
研究组 & 干预措施
BDP/formoterol NEXT DPI
Experimental
Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
干预措施: BDP/formoterol NEXT DPI (Drug)
结局指标
主要结局
Lung deposition of BDP and Formoterol (expressed as % of emitted dose) when inhaled using the NEXT dry powder inhaler
时间窗: Immediately after dosing
Calculated using the individual Gamma camera images and the regions of interest defined from the 81mKrypton-ventilation scan.
次要结局
- Distribution of lung deposition(Immediately after dosing)
- Extrathoracic deposition(Immediately after dosing)
- Plasma pharmacokinetics of formoterol, BDP and its monopropionate metabolite (B17MP)(over 24 h post dose)
- Exhaled activity(Immediately after dosing)
- Lung function parameters(over 24 h post dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD PatientsChronic Obstructive Pulmonary DiseaseAsthmaNCT02975843Chiesi Farmaceutici S.p.A.28
已完成
1 期
Foster With or Without Charcoal Block or Aerochamber PlusHealthy VolunteersNCT01280175Chiesi Farmaceutici S.p.A.13
已完成
不适用
Evaluating lung deposition and pharmacokinetics after controlled inhalation of a radiotracer containing tobramycin aerosol in patients with Cystic Fibrosis1000401810010613Cystic FibrosisNL-OMON33572Apotheek Haagse Ziekenhuizen18
终止
3 期
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant RecipientsLung TransplantationLung DiseasesNCT00235651University of Pittsburgh12
已完成
1 期
Lung Deposition Via Different Inhalation DevicesHealthy VolunteersNCT00975754AstraZeneca16